Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment

The American Journal of Cardiology
J T Bigger

Abstract

The Cardiac Arrhythmia Suppression Trial (CAST) is a randomized, placebo-controlled, double-blind, multicenter clinical trial involving 27 centers and more than 100 hospitals in North America and Europe to test the 1-tailed hypothesis that suppression of ventricular arrhythmias in patients with left ventricular dysfunction after myocardial infarction will reduce arrhythmic death. Since April 18, 1989, the CAST is enrolling patients aged less than 80 years with greater than or equal to 6 ventricular premature complexes and left ventricular ejection fraction less than or equal to 40%. Sustained ventricular tachycardia, class IV congestive heart failure or class IV angina pectoris are exclusion criteria. During a prerandomization period, antiarrhythmic drugs are titrated to suppress ventricular arrhythmias. If greater than or equal to 80% suppression is achieved during open-label titration, patients are randomized to the effective dose or to a matched placebo. If only partial suppression (1 to 79%) is achieved, patients are eligible for a substudy that randomizes them to the best dose found during open-label titration or to placebo. The only patients not randomized to treatment are those with increased arrhythmias or drug intolera...Continue Reading

Associated Clinical Trials

References

Oct 6, 1977·The New England Journal of Medicine·W RubermanS Shapiro
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Aug 10, 1989·The New England Journal of Medicine·J N Ruskin
Nov 11, 1989·BMJ : British Medical Journal·P H HeldC D Furberg
Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Aug 29, 1986·The American Journal of Cardiology·T TordjmanB Lown
Jan 1, 1987·Journal of the American College of Cardiology·A A de PaolaH R Kay
Feb 1, 1988·The American Journal of Cardiology·W SlaterB Lown
Aug 4, 1988·The New England Journal of Medicine·J D MinardoE N Prystowsky
Apr 30, 1987·The American Journal of Cardiology·J T Bigger, D I Sahar
Jan 1, 1987·The American Journal of Cardiology·J MorganrothG Chao
Jan 1, 1982·Progress in Cardiovascular Diseases·G S MayD L DeMets
Sep 1, 1982·The American Journal of Cardiology·T B GraboysR DeSilva
Sep 22, 1983·The American Journal of Cardiology·C D Furberg
Jul 1, 1984·The American Journal of Cardiology·J MukharjiD S Raabe

❮ Previous
Next ❯

Citations

Mar 1, 1991·Journal of Clinical Pharmacology·E M Vaughan Williams
Dec 1, 1990·Journal of the American College of Cardiology·E C Keung
Jun 1, 1991·Journal of the American College of Cardiology·M E WechslerE G Giardina
Apr 25, 2007·Diabetes, Obesity & Metabolism·P M Spooner
Nov 1, 1990·Pacing and Clinical Electrophysiology : PACE·E N PrystowskyT K Knilans
Jan 1, 1995·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·B H KenKnightD J Lang
Apr 1, 1990·Mayo Clinic Proceedings·C J Lavie, B J Gersh
Jul 1, 1996·Psychosomatics·J L Straus, S von Ammon Cavanaugh
Aug 2, 2003·Biological Psychiatry·Steven P Roose
Jun 15, 2005·Psychosomatic Medicine·Steven P Roose, Marissa Miyazaki
Jan 1, 1996·Journal of Cardiovascular Pharmacology and Therapeutics·J A Reiffel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.